# A Study of SC10914 in Patients With Advanced Solid Tumors

> **NCT02940132** · PHASE1 · UNKNOWN · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SC10914

## Key facts

- **NCT ID:** NCT02940132
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-03
- **Final completion:** 2018-05
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02940132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02940132, "A Study of SC10914 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02940132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*